1. Disease and Case Topics
Early Stage Favorable Hodgkin Lymphoma

Classical Hodgkin Lymphoma

Residual PET-positive Disease

Hyperglycemia during Chemotherapy

Pulmonary Toxicity from Bleomycin

Mixed Cellularity Hodgkin Lymphoma

Nodular Sclerosis Subtype

Orbital Lymphoma

Marginal Zone Lymphoma

MALT Lymphoma

Primary Cutaneous Lymphoma

2. Treatment Planning and Techniques
Involved Site Radiation Therapy (ISRT)

PTV Margin for Lymphoma (Planning Target Volume)

PTV 30 Gy for Residual Disease

PTV 27 Gy for Microscopic Disease

IMRT vs. 3D CRT in Hodgkin Lymphoma

VMAT (Volumetric Modulated Arc Therapy)

Static Field IMRT vs. VMAT

Electrons vs. Photons for Orbital Lymphoma

Supine Positioning with Thermoplastic Mask

PET/CT Simulation Differences (Arms Up vs Arms Down)

Matching Pre-chemotherapy Tumor Extent

3. Radiation Dose and Constraints
30 Gy Standard Dose

27 Gy for Elective Regions

Boost Dose to 36–40 Gy for Deauville 4–5 Disease

Salivary Gland Sparing Techniques

Parotid Mean Dose Targets

Submandibular Gland Constraints

Oral Cavity Dose Constraints (Mean <5 Gy)

Thyroid Dose Constraints (V25 < 63.5%)

Contralateral Neck Dose Sparing

Low-dose Spillage Considerations (Second Cancer Risk)

4. Chemotherapy Considerations
ABVD Chemotherapy

AVD (Omission of Bleomycin)

Hyperglycemia and Chemotherapy

ViaCOP (Escalated Chemotherapy)

Brentuximab-containing Regimens (Brief mention)

2 Gy × 2 Fractions ("Boom Boom Regimen")

5. PET Scan Interpretation and Response
Deauville Score 1–5

Deauville 3 vs. Deauville 4 Significance

Interim PET after 2 Cycles of ABVD

PET-Adapted Strategies

Positive Interim PET Outcomes

PET as Prognostic Tool

6. Clinical Trials and Study References
GHSG HD10 Study (German Hodgkin Study Group)

EORTC H10 Study (European Organization for Research and Treatment of Cancer)

GHSG HD16 Study

Chelsea Pinnix Study on Low-Dose Orbital Radiation

NCCN Guidelines for Hodgkin Lymphoma (Dose Constraints Table)

7. Special Radiation Approaches
2 Gy × 2 for Follicular, Marginal Zone, and Mantle Cell Lymphomas

Palliative Radiation Use Cases

Use of 4 Gy for Stage 1 Indolent Orbital Lymphoma

Low-dose Radiation for Advanced/Refractory Hodgkin Lymphoma

Partial Arc VMAT for Low Dose to Contralateral Structures

Full Arc vs Partial Arc Planning Considerations (especially in young patients)

8. Practical Clinical Tips
Importance of Adjusting Dose Constraints Based on Prescription Dose

Ipsilateral vs Contralateral Sparing Priorities

Modifying Templates for Lymphoma vs. Head and Neck Cancer

Insurance Approvals and Justifying IMRT/VMAT

Salvage Treatments for Hodgkin Lymphoma

Risk of Second Malignancy with High Low-dose Radiation Volumes